Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | TACR3 | P29371 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | LATS1 | O95835 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919460 | 0.95 | ACACB (0.39) | ACACBACACAMEN1KMT2AGAA | |
| SCHEMBL15919462 | 0.93 | ACACB (0.40) | ACACBACACATACR3MEN1KMT2A | |
| SCHEMBL15919463 | 0.89 | ACACB (0.41) | ACACBACACAMEN1KMT2AGAA | |
| SCHEMBL15919295 | 0.82 | MAPT (0.37) | TACR3MEN1KMT2AGAALATS1 | |
| SCHEMBL15919549 | 0.80 | ACACB (0.42) | ACACBACACATACR3MEN1KMT2A | |
| SCHEMBL15919535 | 0.80 | ACACB (0.40) | ACACBACACAMEN1KMT2AGAA | |
| SCHEMBL17327512 | 0.78 | LATS1 (0.36) | ACACBTACR3MEN1KMT2ALATS1 | |
| SCHEMBL15919481 | 0.78 | TACR3 (0.40) | ACACBACACATACR3MEN1KMT2A | |
| SCHEMBL17323691 | 0.78 | ACACB (0.35) | ACACBACACATACR3MEN1KMT2A | |
| SCHEMBL15919465 | 0.78 | LATS1 (0.38) | TACR3MEN1KMT2AGAALATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ACACB 1141/4885ACACA 1262/4885TACR3 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.